VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD

ACKNOWLEDGEMENTS: This study was funded by Opthea Pty Ltd, a 100% owned subsidiary of Circadian Technologies, Victoria, Australia. M.B. is an employee of Opthea. The authors KL, JM, GT, CYG have no financial interest in the products. FIGURE 5. (A – J) The dynamic change in mRNA levels of a panel of angiogenic and inflammatory genes on day 0, 1, 3, 7 and 14 post-laser injury in the ocular tissue of mice treated with IgG (blue) or VGX-300 (red). IgG or VGX-300 was administered on day 0 post-laser injury by IVT injection. The green value in each plot is the area ratio of mRNA levels between IgG and VGX-300 treated groups. (K) The accumulated expression of this gene panel for each treatment group. (L) The normalized accumulated expression of each gene in the VGX-300 compared to IgG group (n=10 mice/group on each sampling day).